Eva Lentsch

Eva Lentsch is a Postdoctoral Fellow at the Tuveson Lab, conducting cutting-edge research in pancreatic cancer therapeutics using CRISPR/Cas technology under the Mildred-Scheel postdoctoral scholarship.

Her academic foundation includes:

• M.D. from University of Halle-Wittenberg, Germany
• Ph.D. from University of Erlangen-Nürnberg, Germany (supervised by Prof. Dr. Robert Grützmann)

Her research specializes in CRISPR-mediated genetic interventions targeting pancreatic cancer pathways. Current work focuses on tumor microenvironment-associated genes and immune checkpoint mechanisms, aiming to uncover novel signaling pathways for therapeutic development. This integrates molecular oncology with advanced gene-editing techniques to address one of oncology's most treatment-resistant malignancies.

Scientific recognition includes:

• Mildred-Scheel Postdoctoral Scholarship for pancreatic cancer research

As a key researcher in the Tuveson Lab, she contributes to collaborative projects investigating CRISPR-based therapeutic approaches, with current work examining tumor-stromal interactions through high-throughput genetic screening methodologies.